Non-Hodgkin's lymphoma vaccine - XEME Biopharma

Drug Profile

Non-Hodgkin's lymphoma vaccine - XEME Biopharma

Alternative Names: Oncoquest-L

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator XEME Biopharma
  • Class Cancer vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Follicular lymphoma

Most Recent Events

  • 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
  • 02 Mar 2016 XEME Biopharma plans a phase II trial for Follicular lymphoma (First-line therapy, Late-stage disease) in USA (NCT02194751)
  • 01 Jun 2014 Phase-II clinical trials in Follicular lymphoma (first-line therapy, late-stage disease) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top